Intravitreal brolucizumab is superior to panretinal laser photocoagulation in preserving visual acuity for patients with proliferative diabetic retinopathy, clinical trial data show.

In patients with type 1 diabetes, use of continuous glucose monitoring (CGM) devices -- alone or with insulin pumps -- was associated with lower odds of developing diabetic retinopathy and ...

STOCKHOLM — At the American Society of Retina Specialists (ASRS) 2024 Annual Meeting, researchers discussed how insights into potential risk factors and new treatments could improve outcomes for ...

Please provide your email address to receive an email when new articles are posted on . Regillo discussed treatment with panretinal photocoagulation vs. anti-VEGF therapy, as well as when to use both.

The phase 3 CONDOR trial found brolucizumab superior to panretinal laser photocoagulation for proliferative diabetic retinopathy, offering better vision outcomes and disease regression. The anti-VEGF ...

Please provide your email address to receive an email when new articles are posted on . APX3330 is an oral, small-molecule Ref-1 inhibitor being developed for treating diabetic retinopathy. It reduced ...

The five human senses include sight, hearing, smell, taste, and touch. While each of these matter for different reasons, they aren't perceived as being equal. For instance, according to a YouGov ...

Use of empagliflozin (Jardiance) was not linked to a lower risk of incident nonproliferative diabetic retinopathy compared with dipeptidyl peptidase-4 (DPP-4) inhibitors among patients with type 2 ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. This piece also marks part ...